Business Wire

Inclusive Dialogue and Compromise Needed to Address Major Issues Impacting Society Today, Reveals International Survey from Philip Morris International

13.6.2022 11:30:00 EEST | Business Wire | Press release

Share

The results of a new international survey released today by Philip Morris International Inc. (PMI) (NYSE: PM) reveal that citizens worldwide are frustrated by divisive and exclusionary approaches to policymaking. More than eight in ten adults surveyed worldwide (82 percent) believe the best solutions to critical global challenges can be found not at the extremes but in the middle ground. Conducted by independent research firm Povaddo for PMI, the survey of more than 44,000 adults in 22 countries shows strong agreement among respondents (88 percent) that when making decisions that affect the lives of a significant portion of the population, leaders must listen to and advocate for the people they represent.

The survey results show support for a balanced approach to tobacco regulation, one that brings together all voices and encourages incremental progress on harm reduction. Specifically, the survey found that:

  • 77 percent agree that the too-often-ignored perspectives of those most directly impacted need to be included in regulatory discussions;
  • 75 percent agree that societal expectations of total abstinence from substances such as nicotine and alcohol are not feasible, and so the government should take steps to reduce the harm of their use; and
  • 72 percent agree that their governments need to consider the role alternative products can play in making their countries smoke-free.

“If we are to address the challenges we face as a society in a meaningful and expeditious way, a more balanced and inclusive approach is required,” said Gregoire Verdeaux, Senior Vice President, External Affairs. “This includes policy decisions that consider first and foremost the people who are most impacted—ensuring their voices are heard and their needs are met—and then bringing all relevant parties to the table, including subject matter experts, private companies, civil society leaders, and others who can contribute to solving the issues at hand.”

Despite increasingly polarized societies worldwide, the survey revealed a strong consensus that finding a middle ground on contentious issues can drive incremental policy change and enable progress:

  • 90 percent of respondents believe that to solve the most pressing societal challenges, leaders need to consider all perspectives—even those that run counter to their own.
  • 88 percent said they would be more likely to vote for leaders who listen to all sides of an issue and adopt sensible approaches that better the lives of ordinary people.
  • Currently, less than a third of adults surveyed (31 percent) believe their views are reflected in the way their governments are addressing critical issues.

Additionally, the survey found that citizens are tired of waiting for change and are willing to compromise to make things happen:

  • 76 percent believe leaders should pursue policy changes that allow for incremental progress on societal issues rather than hold out for sweeping changes that are harder to implement.

Finally, people want companies and business leaders to help drive change:

  • 85 percent of respondents believe that citizens and companies working together will have a more meaningful impact.
  • 77 percent welcome corporate involvement in addressing major issues.

Gregoire Verdeaux said: “In countries across the world, citizens are tired of policymaking logjams and eager for constructive change. In the area of tobacco harm reduction, PMI has long advocated for a sensible approach that prioritizes the interests of current adult smokers and public health. By having balanced and inclusive discussions about the science behind better alternatives and adopting a more people-centric approach, we can accelerate the end of cigarettes. More than a billion people continue to smoke. We must—and can—do better, and that starts with open, fact-based dialogue.”

For additional information and to access the full global data set, visit www.pmi.com/hearallvoices.

Survey Methodology

Povaddo conducted the online survey on behalf of PMI between February 5 and 23, 2022. The survey was fielded among 44,000+ general population adults aged 21 and older in 22 countries: Argentina, Brazil, Bulgaria, Colombia, Costa Rica, the Czech Republic, Dominican Republic, France, Germany, Greece, Italy, Japan, Malaysia, Mexico, the Philippines, Portugal, Serbia, South Africa, South Korea, Spain, the United Kingdom, and the United States. Around 2,000 interviews were conducted in each country (approximately equally split between adults who do and do not use nicotine-containing products). The data are weighted to be representative of the online population in each country on the following variables: age, gender, region, and nicotine use. The results are accurate to a margin of error of ±1 percent.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of preclinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of versions of PMI’s IQOS Platform 1 devices and consumables as modified risk tobacco products (MRTPs), finding that exposure modification orders for these products are appropriate to promote the public health. As of March 31, 2022, PMI’s smoke-free products are available for sale in 71 markets, and PMI estimates that approximately 12.7 million adults around the world, excluding Russia and Ukraine, have already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs. For more information, please visit www.pmi.com and www.pmiscience.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Philip Morris International

David Fraser
Philip Morris International
T. +41 (0)79 843 8603
E. david.fraser@pmi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye